D. V. Babaskin, M. A. Zakharchenko, M. S. Shestakov, T. M. Litvinova, L. I. Babaskina, I. U. Glazkova
D. V. Babaskin*, M. A. Zakharchenko, M. S. Shestakov, T. M. Litvinova, L. I. Babaskina, I. U. Glazkova
Sechenov First Moscow State Medical University, 8-2 Trubetskayast., Moscow, 119991, Russian Federation.
Volume - 16,
Issue - 10,
Year - 2023
To address the tasks of developing opportunities to provide pharmaceutical therapy to the elderly via mobile applications, as well as to expand and improve the market for applications in this functional group, it is vital to investigate the attitudes of seniors toward obtaining and using drug treatment applications. The study goal is to research the reasons preventing senior citizens in Russia from adopting mobile applications for drug treatment by determining their attitudes to applications in general and with an emphasis on differences between potential and actual consumers in particular. The objects of the study are three groups of mobile applications for drug treatment: healthcare applications (mHealth), applications of pharmacy chains and individual pharmacies, and drug search applications (aggregators of medications and their prices). The subjects of the study (survey participants) are 816 elderly users of mobile applications for drug treatment from 37 constituent entities of the Russian Federation. The respondents are divided into two target segments: actual app users (S1) and potential app users (S2). Field research is conducted using the oral survey (24.5%) and online survey methods (75.5%) with a structured questionnaire. The study identifies and examines 14 formative factors and 13 factors that maintain respondents' attitudes to applications. The key personal motivational incentives (10 parameters) and barriers (10 parameters) to the adoption of mobile applications by the elderly are determined and researched. Personal reasons that prevent seniors from adopting mobile applications are established, such as the need to get multiple apps for drug treatment (in S1 – 74.5% of respondents; in S2 – 81.7%), difficulties in learning to use the app (in S1 – 32.3%; in S2 – 64.4%), and deterioration of vision (in S1 – 57.8%; in S2 – 62.3%). An emphasis is put on the especially prominent personal motivational barriers in the age groups of seniors between 65 and 75 and 75 and older. The obtained results point to the main limitations and conditions of implementation of mobile applications from the point of providing drug treatment in Russia. In addition, the findings reveal the opportunities to improve the provision of drug treatment to the elderly through mobile applications by setting limits on applications and possibly leveling out the reasons that prevent seniors from adopting mobile applications.
Cite this article:
D. V. Babaskin, M. A. Zakharchenko, M. S. Shestakov, T. M. Litvinova, L. I. Babaskina, I. U. Glazkova. Development of opportunities to provide medication treatment for seniors through mobile applications. Research Journal of Pharmacy and Technology 2023; 16(10):4741-0. doi: 10.52711/0974-360X.2023.00770
D. V. Babaskin, M. A. Zakharchenko, M. S. Shestakov, T. M. Litvinova, L. I. Babaskina, I. U. Glazkova. Development of opportunities to provide medication treatment for seniors through mobile applications. Research Journal of Pharmacy and Technology 2023; 16(10):4741-0. doi: 10.52711/0974-360X.2023.00770 Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-10-40
1. World report on ageing and health. World Health Organization, Geneva. 2015; 246 р. Available at: https://www.who.int/publications/i/item/9789241565042 (accessed on November 24, 2022).
2. Shakir WA, Mohammed SH. Social problems among Elderly people at Geriatric homes in the Middle Euphrates Governorates. Research J. Pharm. and Tech. 2017; 10(7): 2122-2126. https://doi.org/10.5958/0974-360X.2017.00372.9
3. Sankar S, Srinivasan P, Saravanakumar R. Internet of Things based Ambient assisted living for Elderly People Health Monitoring. Research J. Pharm. and Tech. 2018; 11(9): 3900-3904. https://doi.org/10.5958/0974-360X.2018.00715.1
4. Siddiqua A, Abdullah RK, Kareem NA. Impact of Clinical Pharmacist Intervention towards Polypharmacy in Elderly population-A Systematic Study. Research J. Pharm. and Tech. 2019; 12(6): 2621-2627. https://doi.org/10.5958/0974-360X.2019.00439.6
5. United Nations Department of Economic and Social Affairs. Population Division. World Population
1. Prospects 2022: Summary of Results. UN DESA/POP/2022/TR/NO. 3. United Nations. New York. 2022; 38 р. Available at: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/wpp2022_summary_of_results.pdf (accessed on November 24, 2022).
6. World Health Organization. Age-friendly environments in Europe: indicators, monitoring and assessments. WHO Regional Office for Europe, Copenhagen. 2018; 55 р. Available at: https://www.who.int/publications/i/item/WHO-EURO-2020-1088-40834-55192 (accessed on November 24, 2022).
7. Dovjak P. Frailty in older adults with heart disease. ZeitschriftfürGerontologie und Geriatrie. 2022;55(6):465-70. https://doi.org/10.1007/s00391-022-02079-7
8. García-Domínguez L.Navas P. Verdugo MÁ.Arias VB. Chronic health conditions in aging individuals with intellectual disabilities. International Journal of Environmental Research and Public Health. 2020;17(9):3126. https://doi.org/10.3390/ijerph17093126
9. Golovanova ED. Titova NE.Afanasenkova TE. Argunova IA.Yankovaya TN. Ukolova LA.Bazhenova DS. Prevalence and features of geriatric syndromes treatment in old patients (clinical and epidemiological study). Advances in Gerontology. 2020; 33(2):331-8.https://doi.org/10.34922/AE.2020.33.2.016
10. Han S. Mo G. Gao T. Sun Q. Liu H. Zhang M. Age, sex, residence, and region-specific differences in prevalence and patterns of multimorbidity among older Chinese: Evidence from Chinese longitudinal healthy longevity survey. BMC Public Health. 2022; 22(1):1116. https://doi.org/10.1186/s12889-022-13506-0
11. Li H. Hu YJ. Lin H. Xia H. Guo Y. Wu F. Hypertension and comorbidities in rural and urban Chinese older people: An epidemiological subanalysis from the SAGE study. American Journal of Hypertension. 2021;34(2):183-9. https://doi.org/10.1093/ajh/hpaa146
12. Maggio M.Lauretani F. Prevalence, incidence, and clinical impact of cognitive-motoric risk syndrome in Europe, USA, and Japan: Facts and numbers update 2019. Journal of Cachexia, Sarcopenia and Muscle. 2019Oct;10(5):953-5. https://doi.org/10.1002/jcsm.12476
13. Van Onna M. Boonen A. Challenges in the management of older patients with inflammatory rheumatic diseases. Nature Reviews Rheumatology. 2022;18(6):326-34. https://doi.org/10.1038/s41584-022-00768-6
14. Combes GF.Pellay FX.Radman M. Common cause and mechanism for all pathologies of aging? Médecine Sciences. 2020;36(12): 1129-34. https://doi.org/10.1051/medsci/2020221
15. Khovasova NO.Vorobyeva NM. Tkacheva ON. Kotovskaya YV. Naumov AV. Selezneva EV. Ovcharova LN. The prevalence of anemia and its associations with other geriatric syndromes in subjects over 65 years old: Data of Russian epidemiological study EVKALIPT. Therapeutic Archive. 2022;94(1):24-31. https://doi.org/10.26442/00403660.2022.01.201316
16. Liang B. Tang WW. Zhang WQ. Huang C. Liu Y. Xu F. Liu X. Yuan N. Liu JX.Yi YJ. Xu RH. Hu D. Huang XB. Cao X. Prevalence and associated factors of diabetes mellitus in a very elderly Chinese population: A cross-sectional study. Biomedical and Environmental Sciences. 2020;33(5):315-22. https://doi.org/10.3967/bes2020.043
17. Mullin DS. Stirland LE.Welstead M. Russ TC. Luciano M. Muniz-Terrera G. Prevalence and predictors of motoric cognitive risk syndrome in a community-dwelling older Scottish population: A longitudinal observational study. International Journal of Geriatric Psychiatry. 2022;37(11). https://doi.org/10.1002/gps.5824
18. World health statistics 2022: Monitoring health for the SDGs, sustainable development goals. World Health Organization, Geneva. 2022; 125 р. Available at:https://www.who.int/data/gho/publications/world-health-statistics (accessed on November 24, 2022).
19. Al-Ragawi AM. Zyryanov SK. Ushkalova EA. Butranova OI. Pereverzev AP. Prevalence and risk factors of potentially prescribing omissions in elderly and senile patients: Clinical practice in Russian hospitals. Advances in Gerontology. 2020;33(2):282-8.https://doi.org/10.34922/AE.2020.33.2.009
20. Bo M.Gibello M. Brunetti E.Boietti E. Sappa M. Falcone Y.Aurucci ML. Iacovino M. Fonte G.Cappa G. Prevalence and predictors of inappropriate prescribing according to the screening tool of people's prescriptions and screening tool to alert to right treatment version 2 criteria in older patients discharged from geriatric and internal medicine wards: A prospective observational multicenter study. Geriatrics & Gerontology International. 2019; 19(1): 5-11. https://doi.org/10.1111/ggi.13542
21. Jennings ELM. O'Mahony D. Gallagher PF. Medication-related quality of life (MRQoL) in ambulatory older adults with multi-morbidity and polypharmacy. European Geriatric Medicine. 2022 Jun;13(3):579-83. https://doi.org/10.1007/s41999-021-00573-6
22. Gazizov RM. Foundations of drug therapy in elderly and senile age. Practical Medicine. 2010; 2(41):11-4.
23. Purkiss S.Keegel T.Vally H.Wollersheim D. Estimates of drug treated diabetes incidence and prevalence using Australian administrative pharmaceutical data. International Journal of Population Data Science. 2021;6(1):1398. https://doi.org/10.23889/ijpds.v6i1.1398
24. Simou A. Xanthopoulos A. Giamouzis G. Papagiannis D. Dimos A. Economou D. Skoularigis J.Triposkiadis F. Coexisting morbidity burden in elderly hospitalized patients with and without heart failure. Hellenic Journal of Cardiology. 2022;65:53-5. https://doi.org/10.1016/j.hjc.2022.02.002
25. Wang X. Yao S. Wang M. Cao G. Chen Z. Huang Z. Wu Y. Han L. Xu B. Hu Y. Multimorbidity among two million adults in China. International Journal of Environmental Research and Public Health. 2020;17(10):3395. https://doi.org/10.3390/ijerph17103395
26. Gusev AV. Ivshin AA. Vladzymyrskyy AV. Healthcare in the smartphone: The situation in Russia. Russian Journal of Telemedicine and E-Health. 2021; 7(3):21-31. https://doi.org/10.29188/2712-9217-2021-7-3-21-31
27. mHealth: New horizons for health through mobile technologies: Second global survey on eHealth. World Health Organization, Geneva. 2011; 102 р. Available at:https://apps.who.int/iris/handle/10665/44607 (accessed on November 24, 2022).
28. Al-Arkee S. Mason J. Lane DA. Fabritz L. Chua W. Haque MS. Jalal Z. Mobile apps to improve medication adherence in cardiovascular disease: Systematic review and meta-analysis. Journal of Medical Internet Research. 2021;23(5):e24190. https://doi.org/10.2196/24190
29. Aydin G. Silahtaroglu G. Insights into mobile health application market via a content analysis of marketplace data with machine learning. PLoS One. 2021;16(1):e0244302. https://doi.org/10.1371/journal.pone.0244302
30. Global healthcare mobile application market research report 2022. August 16, 2022; 89 р. Available at:https://www.absolutereports.com/enquiry/request-sample/21487660 (accessed on November 24, 2022).
31. González de León B. León Salas B. Del Pino-Sedeño T. Rodríguez-Álvarez C. Bejarano-Quisoboni D. Trujillo-Martín MM. Mobile applications to improve drug adherence: Review and quality analysis. Atención Primaria. 2021;53(9):102095. https://doi.org/10.1016/j.aprim.2021.102095
32. Istepanian RSH. Mobile health (m-Health) in retrospect: The known unknowns. International Journal of Environmental Research and Public Health. 2022Mar 22;19(7):3747. https://doi.org/10.3390/ijerph19073747
33. Pérez-Jover V. Sala-González M.Guilabert M. Mira JJ. Mobile apps for increasing treatment adherence: Systematic review. Journal of Medical Internet Research. 2019;21(6):e12505. https://doi.org/10.2196/12505
34. SedhomR.McSheaMJ.CohenAB.WebsterJA.MathewsSC. Mobile app validation: A digital health. NPJ Digital Medicine. 2021 Jul 15; 4(1): 111. https://doi.org/10.1038/s41746-021-00476-7
35. The State of Mobile in 2022: How to succeed in a mobile-first world as consumers spend 3.8 trillion hours on mobile devices. Available at:https://www.data.ai/en/insights/market-data/state-of-mobile-2022/ (accessed on November 24, 2022).
36. Babaskin DV. Litvinova TM. Babaskina LI. Krylova ОV. Winter EA. Popular diabetes mobile applications for medication intake monitoring. Research Journal of Pharmacy and Technology. 2022; 15(1): 347-56. https://doi.org/10.52711/0974-360X.2022.00057
37. Babaskin DV. Litvinova TM. Babaskina LI. Ovakimyan AK. Kolevatova KY. Marketing evaluation of consumer preferences in using mobile apps for healthcare to support drug adherence. Periodico Tche Quimica. 2020; 17(35): 1013-27. https://doi.org/10.52571/PTQ.v17.n35.2020.83_BABASKIN_pgs_1013_1027.pdf
38. Buhr L.Schicktanz S. Nordmeyer E. Attitudes toward mobile apps for pandemic research among smartphone users in Germany: National survey. JMIR Mhealthand Uhealth. 2022 ;10(1):e31857. https://doi.org/10.2196/31857
39. Lee B. Ibrahim SA. Zhang T. Mobile apps leveraged in the COVID-19 pandemic in East and South-East Asia: Review and content analysis. JMIR Mhealth and Uhealth. 2021;9(11):e32093. https://doi.org/10.2196/32093
40. mHealth programmes for emergencies (operating levels and types). World Health Organization, Geneva. 2017. Available at:https://gateway.euro.who.int/en/indicators/ehealth_survey_145-mhealth-for-emergencies/ (accessed on November 24, 2022).
41. Saber S, Khodir AE, Maghmomeh AO, Nouh NA, El-Baz AM. COVID-19 Pandemic: current Challenges and future Perspectives. Research Journal of Pharmacy and Technology. 2022; 15(1): 329-7. https://doi.org/10.52711/0974-360X.2022.00054
42. Bhattacharjee A, Chanu NR, Bhattacharya K. COVID-19 Pandemic: A Pragmatic plan for Therapeutic Intervention. Research Journal of Pharmacy and Technology. 2022; 15(6):2862-8. https://doi.org/10.52711/0974-360X.2022.00478
43. Best R. Marketing otpotrebitelia [Market-based management]. 6th ed. MIF,Moscow. 2019; 696 p.
44. Kotler P. Armstrong G. Wong V. Saunders J. Osnovymarketinga [Principles of marketing]. 5th European Ed. Williams, Moscow. 2019;752 p.
45. ICC, ESOMAR. International code on market, opinion and social research and data analytics. ESOMAR. 2016. Available at: https://esomar.org/uploads/attachments/ckqtawvjq00uukdtrhst5sk9u-iccesomar-international-code-english.pdf (accessed on November 24, 2022).
46. Mano R. Mobile apps and health management behaviors: Cost-benefit modeling analysis. JMIR Human Factors. 2021; 8(2):e21251. https://doi.org/10.2196/21251
47. NapalkovaАА.Loksha AV. Savostina SE. Factors affecting the consumers’ interaction with the branded mobile applications. Azimuth of Scientific Research: Economics and Administration. 2019;4(29):288-92. https://doi.org/10.26140/anie-2019-0804-0064
48. Szinay D.Perski O. Jones A.Chadborn T. Brown J. Naughton F. Perceptions of factors influencing engagement with health and well-being apps in the United Kingdom: Qualitative interview study. JMIR Mhealthand Uhealth. 2021; 9(12): e29098. https://doi.org/10.2196/29098
49. Wang C. Qi H. Factors of acceptance and use behavior of mobile health application users: Systematic review. Healthcare. 2021; 9(3): 357. https://doi.org/10.3390/healthcare9030357
50. Patil PA, Jain RS. Theoretical Study and treatment of Novel COVID-19. Res. J. Pharmacology and Pharmacodynamics. 2020; 12(2): 71-72. https://doi.org10.5958/2321-5836.2020.00014.2
51. Kumar R, Chawla A, Gaganpreet, Diksha. A Valuable insight to the novel deadly COVID-19: A Review. Res. J. Pharmacology and Pharmacodynamics. 2020; 12(3): 111-116. https://doi.org/10.5958/2321-5836.2020.00021.X
52. Kishor RS, Ramhari BM. Introduction to Covid-19. Research J. Science and Tech. 2020; 12(4): 338-345. https://doi.org/10.5958/2349-2988.2020.00051.0
53. Mor S, Saini P, Wangnoo SK, Bawa T. Worldwide spread of COVID-19 Pandemic and risk factors among Co-morbid conditions especially Diabetes Mellitus in India. Research J. Pharm. and Tech. 2020; 13(5): 2530-2532. https://doi.org/10.5958/0974-360X.2020.00450.3
54. Zakarya, Zalak A, Alfahoum S, Zohairee R. Exploring COVID-19 Progression Patterns. Research J. Pharm. and Tech. 2022; 15(3): 1299-6. https://doi.org/10.52711/0974-360X.2022.00217